Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.
Clements-Mann
M L
ML
Johns Hopkins University School of Public Health, Baltimore, Maryland, USA. mclement@jhsph.edu
Weinhold
K
K
Matthews
T J
TJ
Graham
B S
BS
Gorse
G J
GJ
Keefer
M C
MC
McElrath
M J
MJ
Hsieh
R H
RH
Mestecky
J
J
Zolla-Pazner
S
S
Mascola
J
J
Schwartz
D
D
Siliciano
R
R
Corey
L
L
Wright
P F
PF
Belshe
R
R
Dolin
R
R
Jackson
S
S
Xu
S
S
Fast
P
P
Walker
M C
MC
Stablein
D
D
Excler
J L
JL
Tartaglia
J
J
Paoletti
E
E
D016915:AIDS Vaccines / Q000009:adverse effects; D000328:Adult; D000917:Antibody Formation; D000920:Antibody-Dependent Cell Cytotoxicity; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000009:adverse effects / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D009500:Neutralization Tests; D011820:Rabies virus / Q000276:immunology; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000009:adverse effects; D014765:Viral Vaccines / Q000009:adverse effects
D016915:AIDS Vaccines; C078788:ALVAC vaccine; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic; D014765:Viral Vaccines